Tuesday, May 28, 2024

HomeStock MarketU.S. dialysis volumes to rebound despite GLP-1 impact

U.S. dialysis volumes to rebound despite GLP-1 impact

Fresenius Headquarters in Bad Homburg, Germany

Philiphotographer/iStock Unreleased via Getty Images

Fresenius Medical Care (NYSE:FMS) expects U.S. dialysis volumes to bounce back this year after a COVID-era slump, its CEO Helen Giza says, even as obesity drugmaker Novo Nordisk (NVO) is closing in on the renal care market


Source link

Bookmark (0)
ClosePlease login
RELATED ARTICLES
- Advertisment -spot_img

Most Popular

Sponsored Business

- Advertisment -spot_img